Citigroup maintains CRSP (CRISPR Therapeutics AG) at Buy Feb 2026

Citigroup on February 16, 2026 maintained CRSP at Buy and raised the price target to $80 from $77. This CRSP analyst rating update signals confidence in CRISPR Therapeutics AG’s pipeline and value upside potential. We track the change and explain what it means for investors.

Meyka AI rates CRSP with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Citigroup action and price target change

Citigroup maintained CRSP at Buy on February 16, 2026. The firm raised its price target to $80 from $77.

Citigroup cited valuation and pipeline progress as reasons for the price target increase. The firm kept the Buy rating rather than upgrade or downgrade, showing steady conviction.

How the CRSP analyst rating affects investors

The CRSP analyst rating influences institutional flows and retail interest. A maintained Buy with a higher price target can nudge momentum traders and long-term investors toward adding shares.

Investors should weigh the rating against fundamentals and risk. We advise comparing Citigroup’s view with other research and company catalysts before trading.

Price target details, valuation and market cap

The new target implies upside versus recent trading levels if the stock moves toward $80. Citigroup’s raise was modest at $3, reflecting fine-tuning rather than major revision.

CRISPR Therapeutics AG has a market cap of $5,093,939,871. That market cap places CRSP among mid-cap biotech peers with binary clinical catalysts and partnership revenue potential.

Historical context of CRSP analyst coverage

Analyst coverage of CRSP has oscillated with pipeline readouts and regulatory milestones. Firms have issued Buy, Hold, and at times speculative ratings tied to study results.

Citigroup’s maintained Buy fits a pattern of cautious optimism from major banks. Historical price targets have typically moved around trial news and licensing updates.

Market reaction, stock performance and near-term catalysts

The February 16 note did not show an immediate price change in the entry record. Market moves may follow data releases, partnership news, or broader biotech sentiment.

Key near-term catalysts include clinical readouts and corporate updates. Investors should watch trial timelines and competitor actions that could affect CRSP share momentum.

Meyka AI perspective and next steps for investors

We use Meyka AI’s real-time analyst tracking to flag this maintained Buy and target increase. The change reinforces a constructive view but not a dramatic shift.

Investors should use the CRSP analyst rating alongside valuation, pipeline milestones, and risk tolerance. Diversify exposure and consider position sizing around clinical event risk.

Final Thoughts

Citigroup’s February 16, 2026 note kept CRSP at Buy while nudging the price target to $80. The maintained rating shows continued analyst confidence rather than a rethought thesis. For investors, this signal supports constructive interest but not a clear trigger to add full positions without further confirmation.

Meyka AI rates CRSP with a grade of B, reflecting its mid-cap biotech status, growth prospects, and mixed event risk. Use the CRSP analyst rating as one input. Compare Citigroup’s view with broader coverage, watch clinical catalysts, and align any trade with your risk limits. Sources include primary analyst notes and market summaries.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.